Medopharm’s praziquantel prequalified
M
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
News
New artesunate injection prequalified
M
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
Guilin’s artemether/lumefantrine dispersible tablets prequalified
M
WHO Prequalification Unit (PQT) added the below new products to its prequalified list:
S Kant’s SP dispersible tablet co-packed with amodiaquine dispersible tablet prequalified
M
WHO Prequalification Unit (PQT) added the below new products to its prequalified list:
S Kant’s pyrimethamine/sulfadoxine dispersible tablets prequalified
M
WHO Prequalification Unit (PQT) added the below new products to its prequalified list:
First albendazole prequalified
M
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
Public announcement to TB in vitro diagnostics manufacturers, procurement agencies and national TB programmes on inclusion of WHO Prequalification for TB in vitro diagnostics
IVD
The World Health Organization (WHO), through its Prequalification Unit and Global Tuberculosis Programme, would like to announce future changes to the WHO procedure to determine procurement eligibi
Macleods’ 100mg isoniazid dispersible tablet prequalified
M
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
First biosimilars prequalified after full assessment
M
WHO Prequalification Unit (PQT) added the below new products to its prequalified list:
Emcure’s dolutegravir/lamivudine/tenofovir tablet prequalified
M
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
Ipca’s sulfamethoxazole/trimethoprim prequalified
M
WHO Prequalification Unit (PQT) added the below new products to its prequalified list:
IMPORTANT WITHDRAWAL NOTICE - AmBisome Liposomal Amphotericin B 50mg Powder for Concentrate for Dispersion for Infusion (HA705) - Minisart® Filter
IS
M
On 05 February 2021, Gilead Sciences Ltd.
Lab Leon Farma’s levonorgestrel prequalified
M
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
Macleods’ sulfamethoxazole/trimethoprim prequalified
M
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
Dong-A’s clofazimine prequalified
M
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
Micro Labs dolutegravir prequalified
M
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
Amgen’s trastuzumab prequalified
M
WHO Prequalification Unit (PQT) added the below new products to its prequalified list:
Mylan’s trastuzumab prequalified
M
WHO Prequalification Unit (PQT) added the below new products to its prequalified list:
Laurus’ daclatasvir prequalified
M
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
Nitrosamine concerns for rifapentine and rifampicin - Update and FAQs
M
For an update on nitrosamine concerns for rifapentine and rifampicin, click on attached FAQ document.
First velpatasvir active pharmaceutical ingredient (API) prequalified
M
Velpatasvir (WHOAPI-353) manufactured by Mylan Laboratories Ltd has been prequalified by the WHO Prequalification Unit - Medicines Team (PQT/MED) under its API prequalification procedure.
First ever vaccine listed under WHO emergency use
V
On 13 November 2020, WHO listed the nOPV2 vaccine (Bio Farma, Indonesia) for eme
First dihydroartemisinin/piperaquine 30mg/240mg dispersible tablet prequalified
M
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
First pretomanid prequalified
M
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
Remdesivir removed from the PQT Invitations for Expression of Interest (EOIs) (FPPs and APIs)
M
Remdesivir removed from the PQT Invitations for Expression of Interest (EOIs) (FPPs and APIs).
See link for recent World Health Organization (WHO) recommendations:
New Invitation for Expression of Interest (EOI) for Active Pharmaceutical Ingredients (APIs) published
M
New Invitation for Expression of Interest (EOI) for Active Pharmaceutical Ingredients (APIs) published
New Invitation for Expression of Interest (EOI) to manufacturers of antimalarial medicines published
M
New Invitation for Expression of Interest (EOI) to manufacturers of antimalarial medicines published
New Invitation for Expression of Interest (EOI) for HIV infection and related diseases medicines published
M
New Invitation for Expression of Interest (EOI) for HIV/AIDS medicines published
Draft TSS 7 - Annex 1: Qualification of usability for self-testing with rapid diagnostic tests to detect hepatitis C antibody - available for public comment
IVD
The DRAFT TSS 7 - Annex 1 Qualification of usability for self-testing with rapid diagnostic tests to detect hepatitis C antibody is now avaiable for public comments.